Klotho has dual protective effects on cisplatin-induced acute kidney injury

Kidney International

Volumn 85, Issue 4, 2014, Pages 855-870

  Panesso, Monica C ^a   Shi, Mingjun ^b   Cho, Han J ^b   Paek, Jean ^b   Ye, Jianfeng ^b   Moe, Orson W ^a,b   Hu, Ming Chang ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Cisplatin; Glucuronidase; Klotho; Nephrotoxicity; Organic cation transporter

Indexed keywords

BETA GLUCURONIDASE; CASPASE 3; CIMETIDINE; CISPLATIN; CREATININE; GELATINASE; KLOTHO PROTEIN; LIPOCALIN; MESSENGER RNA; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 2;

ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CELL SURFACE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; MOUSE; NEPHROTOXICITY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RENAL PROTECTION; UPREGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG UPTAKE; KIDNEY CELL; MALE; NUCLEOTIDE SEQUENCE; WILD TYPE; ANIMAL; CELL LINE; CHEMICALLY INDUCED; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; HAMSTER; HUMAN; KIDNEY TUBULE; METABOLISM; TRANSGENIC MOUSE;

ACUTE KIDNEY INJURY; ANIMALS; APOPTOSIS; CELL LINE; CHO CELLS; CISPLATIN; CRICETINAE; CRICETULUS; GLUCURONIDASE; HUMANS; KIDNEY TUBULES; MALE; MICE, TRANSGENIC; ORGANIC CATION TRANSPORT PROTEINS; RATS;

EID: 84897954107     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.489     Document Type: Article

References (75)

1. Lippman AJ, Helson C, Helson L et al. Clinical trials of cisdiamminedichloroplatinum (NSC-119875). Cancer Chemother Rep 1973; 57: 191-200.
2. Hardaker WT Jr., Stone RA, McCoy R. Platinum nephrotoxicity. Cancer 1974; 34: 1030-1032.
3. Gaspari F, Cravedi P, Mandala M et al. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-Associated lipocalin excretion: A pilot prospective case-control study. Nephron Clin Pract 2010; 115: C154-c160.
4. Launay-Vacher V, Rey JB, Isnard-Bagnis C et al. Prevention of cisplatin nephrotoxicity: State of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008; 61: 903-909.
5. Yao X, Panichpisal K, Kurtzman N et al. Cisplatin nephrotoxicity: A review. Am J Med Sci 2007; 334: 115-124.
6. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
7. Sugiura H, Yoshida T, Tsuchiya K et al. Klotho reduces apoptosis in experimental ischaemic acute renal failure. Nephrol Dial Transplant 2005; 20: 2636-2645.
8. Hu MC, Shi M, Zhang J et al. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int 2010; 78: 1240-1251.
9. Matsumura Y, Aizawa H, Shiraki-Iida T et al. Identification of the human klotho gene and its two transcripts encoding membrane and secreted Klotho protein. Biochem Biophys Res Commun 1998; 242: 626-630.
10. Chen CD, Podvin S, Gillespie E et al. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA 2007; 104: 19796-19801.
11. Bloch L, Sineshchekova O, Reichenbach D et al. Klotho is a substrate for alpha-, beta-And gamma-secretase. FEBS Lett 2009; 583: 3221-3224.
12. Hu MC, Moe OW. Klotho as a potential biomarker and therapy for acute kidney injury. Nat Rev Nephrol 2012; 8: 423-429.
13. Hu MC, Shi M, Cho HJ et al. The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection. Kidney Int 2013; 84: 468-481.
14. Hu MC, Shiizaki K, Kuro-o M et al. Fibroblast growth factor 23 and Klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013; 75: 503-533.
15. Doi S, Zou Y, Togao O et al. Klotho inhibits transforming growth factorbeta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011; 286: 8655-8665.
16. Yoon HE, Ghee JY, Piao S et al. Angiotensin II blockade upregulates the expression of Klotho, the anti-Ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrol Dial Transplant 2011; 26: 800-813.
17. Moreno JA, Izquierdo MC, Sanchez-Nino MD et al. The inflammatory cytokines TWEAK and TNFalpha reduce renal klotho expression through NFkappaB. J Am Soc Nephrol 2011; 22: 1315-1325.
18. Havasi A, Borkan SC. Apoptosis and acute kidney injury. Kidney Int 2011; 80: 29-40.
19. Salahudeen AK, Haider N, Jenkins J et al. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol 2008; 294: F1354-F1365.
20. Wei Q, Dong G, Franklin J et al. The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 2007; 72: 53-62.
21. Sugiura H, Yoshida T, Mitobe M et al. Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrol Dial Transplant 2010; 25: 60-68.
22. Ikushima M, Rakugi H, Ishikawa K et al. Anti-Apoptotic and antisenescence effects of Klotho on vascular endothelial cells. Biochem Biophys Res Commun 2006; 339: 827-832.
23. Wang J, Pabla N, Wang CY et al. Caspase-mediated cleavage of ATM during cisplatin-induced tubular cell apoptosis: Inactivation of its kinase activity toward p53. Am J Physiol Renal Physiol 2006; 291: F1300-F1307.
24. Liu H, Fergusson MM, Castilho RM et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science 2007; 317: 803-806.
25. Fukuishi N, Gemba M. Use of cultured renal epithelial cells for the study of cisplatin toxicity. Jpn J Pharmacol 1989; 50: 247-249.
26. Sugiura H, Yoshida T, Shiohira S et al. Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. Am J Physiol Renal Physiol 2012; 302: F1252-F1264.
27. Horbelt M, Wotzlaw C, Sutton TA et al. Organic cation transport in the rat kidney in vivo visualized by time-resolved two-photon microscopy. Kidney Int 2007; 72: 422-429.
28. Liang XJ, Shen DW, Chen KG et al. Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescencelabeled platinum. J Cell Physiol 2005; 202: 635-641.
29. Burckhardt G, Wolff NA. Structure of renal organic anion and cation transporters. Am J Physiol Renal Physiol 2000; 278: F853-F866.
30. Pelis RM, Suhre WM, Wright SH. Functional influence of N-glycosylation in OCT2-mediated tetraethylammonium transport. Am J Physiol Renal Physiol 2006; 290: F1118-F1126.
31. Hu MC, Shi M, Zhang J et al. Klotho: A novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010; 24: 3438-3450.
32. Chang Q, Hoefs S, van der Kemp AW et al. The beta-glucuronidase Klotho hydrolyzes and activates the TRPV5 channel. Science 2005; 310: 490-493.
33. Cha SK, Hu MC, Kurosu H et al. Regulation of renal outer medullary potassium channel and renal K(+) excretion by Klotho. Mol Pharmacol 2009; 76: 38-46.
34. Wang DS, Jonker JW, Kato Y et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002; 302: 510-515.
35. Green RM, Lo K, Sterritt C et al. Cloning and functional expression of a mouse liver organic cation transporter. Hepatology 1999; 29: 1556-1562.
36. Goldstein RS, Mayor GH. Minireview. The nephrotoxicity of cisplatin. Life Sci 1983; 32: 685-690.
37. Jonker JW, Wagenaar E, Van Eijl S et al. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 2003; 23: 7902-7908.
38. Blachley JD, Hill JB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 1981; 95: 628-632.
39. Chopra S, Kaufman JS, Jones TW et al. Cis-diamminedichlorplatinuminduced acute renal failure in the rat. Kidney Int 1982; 21: 54-64.
40. Wei Q, Dong G, Yang T et al. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 2007; 293: F1282-F1291.
41. Molitoris BA, Dagher PC, Sandoval RM et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009; 20: 1754-1764.
42. Jiang M, Wang CY, Huang S et al. Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway. Am J Physiol Renal Physiol 2009; 296: F983-F993.
43. Han X, Yue J, Chesney RW. Functional TauT protects against acute kidney injury. J Am Soc Nephrol 2009; 20: 1323-1332.
44. Medici D, Razzaque MS, Deluca S et al. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol 2008; 182: 459-465.
45. Mitobe M, Yoshida T, Sugiura H et al. Oxidative stress decreases klotho expression in a mouse kidney cell line. Nephron Exp Nephrol 2005; 101: E67-e74.
46. Haruna Y, Kashihara N, Satoh M et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci USA 2007; 104: 2331-2336.
47. Benedetti G, Fredriksson L, Herpers B et al. TNF-Alpha-mediated NF-kappaB survival signaling impairment by cisplatin enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells. Biochem Pharmacol 2013; 85: 274-286.
48. Linkermann A, Himmerkus N, Rolver L et al. Renal tubular Fas ligand mediates fratricide in cisplatin-induced acute kidney failure. Kidney Int 2011; 79: 169-178.
49. Tsuruya K, Ninomiya T, Tokumoto M et al. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 2003; 63: 72-82.
50. Thurston RD, Larmonier CB, Majewski PM et al. Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis. Gastroenterology 2010; 138: 1384-1394, e1381-1394, e1381-1382.
51. Maekawa Y, Ishikawa K, Yasuda O et al. Klotho suppresses TNF-Alphainduced expression of adhesion molecules in the endothelium and attenuates NF-kappaB activation. Endocrine 2009; 35: 341-346.
52. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer 1993; 67: 1171-1176.
53. Zhang L, Dresser MJ, Chun JK et al. Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A). J Biol Chem 1997; 272: 16548-16554.
54. Schomig E, Spitzenberger F, Engelhardt M et al. Molecular cloning and characterization of two novel transport proteins from rat kidney. FEBS Lett 1998; 425: 79-86.
55. Mooslehner KA, Allen ND. Cloning of the mouse organic cation transporter 2 gene, Slc22a2, from an enhancer-Trap transgene integration locus. Mamm Genome 1999; 10: 218-224.
56. Safirstein R, Winston J, Goldstein M et al. Cisplatin nephrotoxicity. Am J Kidney Dis 1986; 8: 356-367.
57. Miura K, Goldstein RS, Pasino DA et al. Cisplatin nephrotoxicity: Role of filtration and tubular transport of cisplatin in isolated perfused kidneys. Toxicology 1987; 44: 147-158.
58. Cilenti L, Kyriazis GA, Soundarapandian MM et al. Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am J Physiol Renal Physiol 2005; 288: F371-F379.
59. Okuda M, Tsuda K, Masaki K et al. Cisplatin-induced toxicity in LLC-PK1 kidney epithelial cells: Role of basolateral membrane transport. Toxicol Lett 1999; 106: 229-235.
60. Endo T, Kimura O, Sakata M. Carrier-mediated uptake of cisplatin by the OK renal epithelial cell line. Toxicology 2000; 146: 187-195.
61. Ludwig T, Riethmuller C, Gekle M et al. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 2004; 66: 196-202.
62. Vickers AE, Rose K, Fisher R et al. Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 2004; 32: 577-590.
63. Filipski KK, Mathijssen RH, Mikkelsen TS et al. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 2009; 86: 396-402.
64. Franke RM, Kosloske AM, Lancaster CS et al. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-Acetyl-beta-Dglucosaminidase. Clin Cancer Res 2010; 16: 4198-4206.
65. Li Q, Peng X, Yang H et al. Contribution of organic cation transporter 3 to cisplatin cytotoxicity in human cervical cancer cells. J Pharm Sci 2012; 101: 394-404.
66. Pabla N, Murphy RF, Liu K et al. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 2009; 296: F505-F511.
67. Katsuda H, Yamashita M, Katsura H et al. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol Pharm Bull 2010; 33: 1867-1871.
68. Abramovitz L, Rubinek T, Ligumsky H et al. KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res 2011; 17: 4254-4266.
69. Wang Y, Chen L, Huang G et al. Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway. PLoS One 2013; 8: E57391.
70. Kurosu H, Yamamoto M, Clark JD et al. Suppression of aging in mice by the hormone Klotho. Science 2005; 309: 1829-1833.
71. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124-136.
72. Kelly KJ, Wu P, Patterson CE et al. LOX-1 and inflammation: A new mechanism for renal injury in obesity and diabetes. Am J Physiol Renal Physiol 2008; 294: F1136-F1145.
73. Barendt WM, Wright SH. The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J Biol Chem 2002; 277: 22491-22496.
74. Pelis RM, Hartman RC, Wright SH et al. Influence of estrogen and xenoestrogens on basolateral uptake of tetraethylammonium by opossum kidney cells in culture. J Pharmacol Exp Ther 2007; 323: 555-561.
75. Zinellu A, Caria MA, Tavera C et al. Plasma creatinine and creatine quantification by capillary electrophoresis diode array detector. Anal Biochem 2005; 342: 186-193.